Economic Evaluation of Heart Failure Management in Colombian Clinics (EconoHeart)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01084564
First received: March 9, 2010
Last updated: NA
Last verified: March 2010
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.
| Condition |
|---|
|
Heart Failure Asthma |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Economic Evaluation of Heart Failure Management in Colombian Clinics |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Primary Outcome Measures:
- To determine cost-effectiveness of Heart Failure management in 3 Heart-specialized clinics in Bogotá Colombia [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy (SMART) when compared with its competitive alternatives [ Designated as safety issue: No ]
| Enrollment: | 300 |
| Study Start Date: | January 2008 |
| Study Completion Date: | June 2008 |
| Primary Completion Date: | June 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
1
moderate to severe uncontrolled asthma
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Study Population
Moderate to severe uncontrolled asthma.
Criteria
Inclusion Criteria:
- Asthma moderate to severe.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01084564
Please refer to this study by its ClinicalTrials.gov identifier: NCT01084564
Sponsors and Collaborators
AstraZeneca
Investigators
| Study Director: | Rodolfo Dennis, M.D. | Pontificia Universidad Javeriana | |
| Principal Investigator: | MARÍA XIMENA ROJAS, M.D. | Pontificia Universidad Javeriana |
More Information
No publications provided
| Responsible Party: | MC MD, AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT01084564 History of Changes |
| Other Study ID Numbers: | NIS-CCO-ATA-2007/1 |
| Study First Received: | March 9, 2010 |
| Last Updated: | March 9, 2010 |
| Health Authority: | Colombia: Institutional Review Board |
Keywords provided by AstraZeneca:
|
Cost-effectiveness analysis Colombia |
Additional relevant MeSH terms:
|
Heart Failure Cardiovascular Diseases Heart Diseases |
ClinicalTrials.gov processed this record on February 27, 2015